Receive our newsletter – data, insights and analysis delivered to you
  1. News
  2. Company News
April 15, 2019

Albireo to assess elobixibat in Phase II trial for liver diseases

Albireo Pharma has announced plans to study elobixibat in a Phase II clinical trial involving adults with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH).

Albireo Pharma has announced plans to study elobixibat in a Phase II clinical trial involving adults with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH).

The drug’s investigational new drug (IND) application has been cleared by the US Food and Drug Administration (FDA).

Elobixibat is a first-in-class, oral, once-daily ileal bile acid transporter (IBAT) inhibitor. The drug has been approved in Japan for the treatment of chronic constipation, except in cases of organic disease.

The Phase II trial will evaluate the safety and efficacy of 5mg elobixibat over 16 weeks in around 46 patients with biopsy-confirmed NASH or suspected NAFLD/NASH based on metabolic syndrome definitions.

“The IND and subsequent trial initiation are an important step for our NASH programme.”

Change in low-density lipoprotein (LDL) cholesterol will be measured as the primary endpoint of the randomised, double-blinded, placebo-controlled, multi-centre trial.

Secondary endpoints of the study include assessment of change in liver fat by imaging, and the levels of alanine transaminase (ALT) and serum bile acids.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

The firm will launch the trial in the second quarter of this year and results are expected next year.

Albireo Pharma president and CEO Ron Cooper said: “The IND and subsequent trial initiation are an important step for our NASH programme, as we apply our expertise in bile acids and leverage our novel IBAT platform to address a large unmet medical need.

“We have a two-pronged approach for NASH development: advancing elobixibat, a well-characterised IBAT inhibitor, into a Phase II trial, and continuing to develop novel preclinical compounds.”

NAFLD is known to impact approximately 25% of people globally. The disease could progress to NASH that causes liver inflammation and damage due to accumulation of fat in the organ.

Risk of liver-related mortality in patients with NASH is ten times greater than the general population and the condition currently lacks approved pharmacologic treatments.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU